Related Experiment Video

Updated: Jul 28, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.7K

GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision

Kai Wang1, Yuhui Chen2, Sarah Ahn2,3

  • 1Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Nature Cancer
|April 26, 2021
PubMed

Insights

Researchers developed GD2-specific CAR T-cells to treat retinoblastoma (RB), a pediatric eye cancer. This innovative therapy successfully eliminated tumor cells in mice, preserving vision and offering hope for improved treatment outcomes.

Area of Science:

  • Ophthalmology
  • Pediatric Oncology
  • Immunotherapy
  • Cancer Research

Background:

  • Retinoblastoma (RB) is a significant pediatric retinal tumor.
  • Overexpression of the ganglioside GD2 is a hallmark of RB.
  • Current treatments can lead to vision loss or eye removal, even with early diagnosis.

Purpose of the Study:

  • To develop and evaluate a novel immunotherapy for retinoblastoma.
  • To assess the efficacy of GD2-specific chimeric antigen receptor T-cells (GD2.CAR-Ts) in eliminating RB tumor cells.
  • To determine if this treatment preserves vision in a preclinical model.

Main Methods:

  • Generation of GD2-specific chimeric antigen receptor T-lymphocytes (GD2.CAR-Ts).
  • Local delivery of GD2.CAR-Ts to mice with in-situ grafted retinoblastoma.
  • Combination therapy involving local release of interleukin-15 (IL-15) via an injectable hydrogel.

Main Results:

  • GD2.CAR-Ts demonstrated successful elimination of retinoblastoma tumor cells in the treated mice.
  • The combination therapy, including IL-15 and hydrogel, enhanced treatment efficacy.
  • Crucially, the treatment did not impair the vision of the mice.

Conclusions:

  • Local delivery of GD2.CAR-Ts, combined with IL-15, is a promising strategy for retinoblastoma treatment.
  • This approach offers a potential organ-sparing therapy for pediatric eye cancer.
  • Further research may lead to improved outcomes and vision preservation in retinoblastoma patients.

More Related Videos

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

7.9K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.